Related Experiment Video
Updated: May 14, 2026
14:39
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
Mepolizumab for severe eosinophilic asthma
1Leukocyte Biology Section, National Heart and Lung Institute, Imperial College London, UK. d.s.robinson@imperial.ac.uk
Expert Review of Respiratory Medicine
|February 1, 2013
Summary
Mepolizumab significantly reduced exacerbations by 50% in severe asthma patients with persistent eosinophilia. This biologic therapy shows promise for a specific subgroup of severe asthmatics, though further research is needed.
Area of Science:
- Immunology
- Pulmonology
- Pharmacology
Background:
- Severe asthma affects a significant patient population with limited treatment options.
- Eosinophilic inflammation plays a key role in severe asthma exacerbations.
- Mepolizumab targets interleukin-5 (IL-5), a key mediator of eosinophilic inflammation.
Discussion:
- This double-blind, placebo-controlled study evaluated mepolizumab's efficacy in severe asthma.
- Patients received intravenous mepolizumab or placebo every 4 weeks for 1 year.
- The study assessed exacerbation rates, asthma symptoms, quality of life, and lung function.
Key Insights:
- Mepolizumab demonstrated a 50% reduction in exacerbation rates across all tested doses compared to placebo.
- No significant improvements were observed in other asthma control measures like symptoms, quality of life, or lung function.
- The findings suggest mepolizumab is beneficial for severe asthma patients with persistent eosinophilia and frequent exacerbations.
Outlook:
- Further research is required to define optimal patient selection criteria for mepolizumab therapy.
- Cost-benefit analyses are necessary to determine the economic viability of mepolizumab in clinical practice.
- Mepolizumab may represent a valuable therapeutic advance for a specific, difficult-to-treat subgroup of severe asthmatics.
Related Concept Videos
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
01:24Antiasthma Drugs: Methylxanthines
Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
01:20Antiasthma Drugs: Muscarinic Receptor Antagonists
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
01:13Asthma III: Clinical Manifestations
Asthma presents with a characteristic pattern of episodic respiratory symptoms that reflect underlying airway inflammation, bronchoconstriction, and mucus hypersecretion. Although severity varies among individuals, certain clinical manifestations are considered hallmarks of the disorder and often guide diagnosis and assessment.Respiratory SymptomsA persistent cough is one of the most common early features of asthma. It is frequently dry and tends to worsen at night or in the early morning,...
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...